Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBT Margin (2022 - 2025)

Historic EBT Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 154.17%.

  • InMed Pharmaceuticals' EBT Margin fell 215000.0% to 154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 171.13%, marking a year-over-year decrease of 338600.0%. This contributed to the annual value of 165.14% for FY2025, which is 16500.0% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' EBT Margin is 154.17%, which was down 215000.0% from 137.07% recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' EBT Margin registered a high of 14.56% during Q2 2023, and its lowest value of 1615.6% during Q4 2021.
  • Moreover, its 5-year median value for EBT Margin was 180.61% (2023), whereas its average is 470.94%.
  • Per our database at Business Quant, InMed Pharmaceuticals' EBT Margin skyrocketed by 15143100bps in 2023 and then tumbled by -1359000bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBT Margin stood at 1615.6% in 2021, then soared by 72bps to 446.61% in 2022, then skyrocketed by 73bps to 119.19% in 2023, then plummeted by -94bps to 231.63% in 2024, then skyrocketed by 33bps to 154.17% in 2025.
  • Its EBT Margin was 154.17% in Q3 2025, compared to 137.07% in Q2 2025 and 168.12% in Q1 2025.